USFDA red flags Torrent Pharma's US-based plant for manufacturing violations

摘要

The USFDA has pulled up Torrent Pharmaceuticals' US-based subsidiary for violations of current good manufacturing practices (cGMP), including a lack of adequately designed equipment and packing material. In a warning letter issued to Torrent Pharma Inc's CEO, Mr. Sanjay Gupta, the USFDA said its inspectors found significant violations of cGMP regulations for finished phar- maceuticals at the company's Levittown (Pennsylvania) based manufacturing facility. The USFDA inspected the plant from March 11 to April 9 this year.